We included the BLAST against nr/nt step because even amplicon sequencing data from communities with a putatively known reference composition will contain contaminant sequences. Contaminants are real, albeit unwanted, biological variation, and should be identified when correcting amplicon errors. While the nr/nt database is imperfect, it is reasonable to expect that Exact matches are far more likely to be real variants than are Others. Output sequences classified as Other, and output sequences classified as One Off that differed by one substitution from a more abundant output sequence, were considered a proxy for false positives. Output sequences classified as Reference or Exact were considered true positives.
Biopharmaceuticals
These specialized therapeutics, including proteins, nucleic acids, and vaccines, have revolutionized the treatment of a wide range of diseases, from cancer and autoimmune disorders to rare genetic conditions.
Biopharaceuticals offer targeted, often more effective, and potentially safer alternatives to traditional small-molecule drugs.
Their development and production involve complex biological processes, requirng specialized expertise and cutting-edge technologies.
Researchers and developers in the biopharmaceutical field are at the forefront of medical innovation, harnessing the power of biology to address unmet medical needs and improve patient outcomes.
Most cited protocols related to «Biopharmaceuticals»
We included the BLAST against nr/nt step because even amplicon sequencing data from communities with a putatively known reference composition will contain contaminant sequences. Contaminants are real, albeit unwanted, biological variation, and should be identified when correcting amplicon errors. While the nr/nt database is imperfect, it is reasonable to expect that Exact matches are far more likely to be real variants than are Others. Output sequences classified as Other, and output sequences classified as One Off that differed by one substitution from a more abundant output sequence, were considered a proxy for false positives. Output sequences classified as Reference or Exact were considered true positives.
Most recents protocols related to «Biopharmaceuticals»
Example 7
Synthetic urine is prepared by dissolving 14.1 g of NaCl, 2.8 g KCl, 17.3 g of urea, 19 ml ammonia water (25%), 0.60 g CaCl2 and 0.43 g MgSO4 in 0.02 mole/L of HCl. The final pH of synthetic urine is adjusted to 6.04 by using HCl and ammonia water.
40 mg Sigma creatinine is dissolved in 10 ml of synthetic urine solution. 3 mg of human albumin is dissolved in 10 ml of synthetic urine solution to prepare the micro albumin solution.
4 mg Sigma hemin is dissolved in 20 ml of synthetic urine, 20 μL Hemin solution is used as a receptor for urine albumin detection at different creatinine concentration.
A desired volume of the biological sample (synthetic urine) is taken and dispensed on the electrode of the biosensor device and the corresponding cyclic voltammogram is obtained by the CHI-Electrochemical workstation using the potential window, that varies from 0 V to −1 V with scan rate of 0.1 V/sec.
The albumin content in the urine sample binds hemin thereby demonstrates a linear decrease in peak redox current with urine albumin concentration as shown in
The values of concentrations of the urine albumin (mg/L) and creatinine for different samples is shown in Table 4.
Example 49
The functional activity of compounds was determined in a cell line where p70S6K is constitutively activated. Test article was dissolved in DMSO to make a 10 μM stock. PathScan® Phospho-S6 Ribosomal Protein (Ser235/236) Sandwich ELISA Kit was purchased from Cell Signaling Technology. A549 lung cancer cell line, was purchased from American Type Culture Collection. A549 cells were grown in F-12K Medium supplemented with 10% FBS. 100 μg/mL penicillin and 100 μg/mL streptomycin were added to the culture media. Cultures were maintained at 37° C. in a humidified atmosphere of 5% CO2 and 95% air. 2.0×105 cells were seeded in each well of 12-well tissue culture plates for overnight. Cells were treated with DMSO or test article (starting at 100 μM, 10-dose with 3 fold dilution) for 3 hours. The cells were washed once with ice cold PBS and lysed with 1× cell lysis buffer. Cell lysates were collected and samples were added to the appropriate wells of the ELISA plate. Plate was incubated for overnight at 4° C. 100 μL of reconstituted Phospho-S6 Ribosomal Protein (Ser235/236) Detection Antibody was added to each well and the plate was incubated at 37° C. for 1 hour. Wells were washed and 100 μl of reconstituted HRP-Linked secondary antibody was added to each well. The plate was incubated for 30 minutes at 37° C. Wash procedure was repeated and 100 μL of TMB Substrate was added to each well. The plate was incubated for 10 minutes at 37° C. 100 μL of STOP Solution was added to each well and the absorbance was read at 460 nm using Envision 2104 Multilabel Reader (PerkinElmer, Santa Clara, CA). IC50 curves were plotted and IC50 values were calculated using the GraphPad Prism 4 program based on a sigmoidal dose-response equation.
Unless otherwise noted, compounds that were tested had an IC50 of less than 50 μM in the S6K Binding assay. A=less than 0.05 μM; B=greater than 0.05 μM and less than 0.5 μM; C=greater than 0.5 μM and less than 10 μM;
Example 19
To confirm bioactivity of 3 and 7, experiments were performed with the HH cell line, a mature T cell line derived from peripheral blood of a patient with aggressive cutaneous T cell leukemia/lymphoma (ATCC® CRL-2105™) which been demonstrated to only express the IL-2Rβ/γ. One of the earliest events in cytokine mediated activation of lymphocytes such as CD8+ T cells and NK cells is Janus Associated Kinase mediated phosphorylation and activation of Signal transducer and activator of transcription (pSTAT5). Thus, pSTAT5 was used to measure biological activity of 3 and 7 alongside 12. 3 demonstrated clear bioactivity in IL-2Rβ/γ expressing HH cells (EC50: 773 ng/ml) that was approximately 3.5 fold lower than 12 (EC50: 233 ng/ml). Additionally, 7 induced bioactivity (EC50: 756 ng/ml) very similar to 3, demonstrating that 7 retains bioactivity after being released from prodrug 5 even after accelerated (stress) conditions.
Example 4
To determine enzymatic activities, 500 mg of tobacco leaf tissue collected from leaf 23 of three biological replicates of was ground in 1 ml HEPES extraction buffer (100 mM HEPES, 2 mM dithiothreitol (DTT), 1 mM EDTA, pH 7.5) and 100 mg of polyvinylpyrrolidone was added during grinding. Following centrifugation (13,000 g, 10 min, 4° C.), the enzyme activities were measured using an isotopic method as described by Capell et al. (1998) by measuring the release of 14CO2. L-[1-14C]Arg and L-[1-14C]Orn were used as radioactive substrates.
Example 5
Probes of the invention include a porous material, such as paper, that can function to both separate chemicals in biological fluids before in situ ionization by mass spectrometry. In this Example, the porous material for the probe was chromatography paper. As shown in
The chromatography paper thus allowed for sample collection, analyte separation and analyte ionization. This represents a significant simplification of coupling chromatography with MS analysis. Chromatography paper is a good material for probes of the invention because such material has the advantage that solvent movement is driven by capillary action and there is no need for a syringe pump. Another advantage is that clogging, a serious problem for conventional nanoelectrospray sources, is unlikely due to its multi-porous characteristics. Therefore, chromatography paper, a multi-porous material, can be used as a microporous electrospray ionization source.
Top products related to «Biopharmaceuticals»
More about "Biopharmaceuticals"
These innovative therapeutics, including proteins, nucleic acids, and vaccines, have revolutionized the treatment of a wide range of diseases, from cancer and autoimmune disorders to rare genetic conditions.
Biopharaceuticals offer targeted, often more effective, and potentially safer alternatives to traditional small-molecule drugs.
Their development and production involve complex biological processes, requiring specialized expertise and cutting-edge technologies like TRIzol reagent, FBS, Prism 8, RNeasy Mini Kit, TRIzol, GraphPad Prism 7, Agilent 2100 Bioanalyzer, Prism 9, and Prism 6.
Researchers and developers in the biopharmaceutical field are at the forefront of medical innovation, harnessing the power of biology to address unmet medical needs and improve patient outcomes.
Biopharmaceuticals, also known as biologics or biotech drugs, have become increasingly important in the treatment of a wide range of conditions, from cancer and autoimmune diseases to rare genetic disorders.
These specialized therapeutics, including recombinant proteins, monoclonal antibodies, gene therapies, and cell-based therapies, offer targeted and often more effective treatments compared to traditional small-molecule drugs.
The development and production of biopharmaceuticals involve complex biological processes, requiring specialized expertise and state-of-the-art technologies.
Researchers in the biopharmaceutical field are at the forefront of medical innovation, leveraging advanced tools and techniques to advance the field and improve patient outcomes.
Discover how PubCompare.ai, the cutting-edge platform, can elevate your biopharmaceutical research through AI-powered protocol comparison and optimization, providing access to a vast repository of protocols from literature, pre-prits, and patents, and leveraging advanced AI algorithms to identify the most effective protocols and products for your research needs.